A single dose of gene-editing therapy slashed 'bad' cholesterol by 62% in an early trial. This result could redefine cardiovascular prevention, offering a potential alternative to daily statins.
The Science Behind the Breakthrough
The Phase 1 trial tested VERVE-102, a gene-editing therapy acquired by Eli Lilly through its $1 billion buyout of Verve Therapeutics. Participants received a high dose of the treatment, which uses CRISPR-based editing to disable a key gene involved in LDL cholesterol production. The 62% reduction is striking, especially because no treatment-related serious adverse events were reported. This safety data matters because Verve previously shelved its first candidate due to safety concerns. Now, with VERVE-102, the safety profile appears improved, though the study is small and preliminary. The gene editing targets the PCSK9 gene, a well-known target for cholesterol reduction. By silencing it, the liver produces less PCSK9 protein, allowing more LDL receptors to clear cholesterol from the blood.
The mechanism is elegant: the therapy uses lipid nanoparticles to deliver the CRISPR system to the liver, where it edits the DNA of liver cells. Once edited, the PCSK9 gene remains permanently disabled, meaning a single injection could provide lifelong benefits. This contrasts with statins, which require daily dosing and are often discontinued due to side effects like muscle pain or poor adherence. Statin adherence is low: studies show only about 50% of patients continue taking them after one year. A one-time therapy could eliminate this problem.
